Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trial.
Flaherty
L E
LE
Wayne State University Medical Center, Detroit, MI.
Liu
P Y
PY
Fletcher
W S
WS
Goodwin
J W
JW
Balcerzak
S P
SP
Daniels
D
D
Stephens
R L
RL
Sondak
V K
VK
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use / Q000633:toxicity*; D003606:Dacarbazine / Q000008:administration & dosage / Q000633:toxicity*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000633:toxicity*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D010045:Outpatients; D012727:Sex Characteristics
D007376:Interleukin-2; D003606:Dacarbazine